Stoke Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

STOK$27.21-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed consolidated statements of operations and comprehensive (loss) income

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Revenue	$11,255	$10,632	$26,808	$183,018
Operating expenses:
Research and development	59,831	37,696	149,004	96,227
Sales, general and administrative	28,739	16,027	73,966	45,942
Total operating expenses	88,570	53,723	222,970	142,169
(Loss) income from operations	(77,315)	(43,091)	(196,162)	40,849
Other income (expense):
Interest income (expense), net	3,665	3,463	10,564	10,141
Other income	6	3	333	59
Total other income (expense)	3,671	3,466	10,897	10,200
(Loss) income before income taxes	$(73,644)	$(39,625)	$(185,265)	$51,049
Provision for income taxes	—	(1,278)	—	—
Net (loss) income	$(73,644)	$(38,347)	$(185,265)	$51,049
Net (loss) income per share:
Basic	$(1.08)	$(0.65)	$(2.81)	$0.88
Diluted	(1.08)	(0.65)	(2.81)	0.85
Weighted-average common shares outstanding:
Basic	68,362,880	58,611,677	65,834,172	58,278,812
Diluted	68,362,880	58,611,677	65,834,172	60,397,681
Comprehensive (loss) income:
Net (loss) income	$(73,644)	$(38,347)	$(185,265)	$51,049
Other comprehensive (loss) gain:
Unrealized (loss) gain on marketable securities	(508)	350	(1,593)	597
Total other comprehensive (loss) gain	$(508)	$350	$(1,593)	$597
Comprehensive (loss) income	$(74,152)	$(37,997)	$(186,858)	$51,646

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.